Mammary Cell News Volume 6.36 | Sep 18 2014

BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity
BMP4 reduces the expression and secretion of granulocyte colony-stimulating factor by inhibiting NF-κB activity in human and mouse tumor lines. [Cancer Res] Abstract

Transmembrane Domain Targeting Peptide Antagonizing ErbB2/Neu Inhibits Breast Tumor Growth and Metastasis
Researchers report a proof-of-concept experiment demonstrating that small peptides interfering with the transmembrane domain of the tyrosine kinase epidermal growth factor receptor ErbB2 exhibit anticancer properties when used at micromolar dosages in a genetically engineered mouse model of breast cancer. [Cell Rep] Full Article | Graphical Abstract

Tamoxifen Induces Apoptosis through Cancerous Inhibitor of Protein Phosphatase 2A Dependent Phospho-Akt Inactivation in Estrogen-Receptor Negative Human Breast Cancer Cells
Scientists tested the efficacy of tamoxifen in a panel of estrogen receptor (ER)-negative breast cancer cell lines and examined the drug mechanism. In total, five ER-negative breast cancer cell lines HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453 and SK-BR-3 were used for in vitro studies. [Breast Cancer Res]
Abstract | Full Article

miR-638 Mediated Regulation of BRCA1 Affects DNA Repair and Sensitivity to UV and Cisplatin in Triple Negative Breast Cancer
Researchers investigated the role of microRNA (miR)-638 in breast cancer prognosis and treatment. Formalin-fixed, paraffin-embedded breast cancer samples were microdissected into normal epithelial cells and invasive ductal carcinoma, and total RNA was isolated. [Breast Cancer Res] Abstract | Full Article

A Kinase Inhibitor Screen Reveals PKC-Dependent Endocytic Recycling of ErbB2 in Breast Cancer Cells
Scientists used a high-content immunofluorescence imaging-based kinase inhibitor screen on SKBR-3 breast cancer cells to identify kinases whose inhibition alters the clearance of cell surface ErbB2 induced by Hsp90 inhibitor 17-AAG. [J Biol Chem] Abstract | Full Article

A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer
CDDO-Imidazolide (CDDO-Im) treatment markedly induced cell cycle arrest at G2/M-phase and apoptosis in the triple-negative breast cancer cell lines, SUM159 and MDA-MB-231. [PLoS One] Full Article

Pttg1 Inhibits TGFβ Signaling in Breast Cancer Cells to Promote Their Growth
Researchers examined breast cancer from the patients and detected significant increases and correlation in pituitary tumor transforming gene 1 (Pttg1) and phosphorylated SMAD3, a key effector of activated transforming growth factor β (TGFβ) receptor signaling pathway. [Tumor Biol] Abstract

Knockdown of ANLN by Lentivirus Inhibits Cell Growth and Migration in Human Breast Cancer
To evaluate the function of anillin (ANLN) in breast cancer cells, researchers employed lentivirus-mediated RNA interference to knock down ANLN expression in two human breast cancer cell lines, MDA-MB-231, and ZR-75-30. [Mol Cell Biochem] Abstract

CLINICAL RESEARCH

Survival after Neoadjuvant Chemotherapy with or without Bevacizumab or Everolimus for HER2-Negative Primary Breast Cancer
Researchers previously showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response rates overall and specifically in patients with triple negative breast cancer. Here, they present disease-free and overall survival analyses. [Clin Cancer Res] Abstract

The Efficacy of Adjuvant Trastuzumab in HER-2 Positive Breast Cancer with Axillary Lymph Node Metastases Accordıng to the Treatment Duration
The authors investigated the efficacy and safety of adjuvant 9-weeks and 52-weeks trastuzumab in axillary lymph node-positive HER-2 positive breast cancer patients. [Curr Med Res Opin] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
TapImmune Inc. reported that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha class II antigenic epitopes. [TapImmune Inc.] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Position – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

PhD Position – Breast Cancer Research (University of Iceland Biomedical Center)

Postdoctoral Positions – Cell Death of Normal Tissue Stem Cells (Sloan-Kettering Institute)

Postdoctoral Fellow – Breast Cancer Translational Research (University of Houston – College of Pharmacy)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast Cancer Metastasis (University of Texas MD Anderson Cancer Center)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.